Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years
BAUS ePoster online library. Reddy D. 06/21/21; 319066; p2-8
Disclosure(s): Deepika Reddy's research was funded by Prostate Cancer UK and has received grants from Sonacare and Imperial College Healthcare Charity to travel to conferences.
Deepika Reddy
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
Focal therapy aims to treat areas of cancer in order to confer oncological control whilst reducing treatment-related functional detriment. To report on oncological outcomes and adverse events following focal HIFU for treating non-metastatic prostate cancer.
Patients and Methods
An analysis of 1829 UK patients with non-metastatic prostate cancer prospectively recorded in the HEAT registry treated with Focal HIFU therapy (Sonablate500 and Sonablate 3G) at nine centres (17/11/2005-30/07/2020). Six months follow-up or greater was available in 1378 (75.3%). Failure-free survival (FFS) was primarily defined as avoidance of salvage whole-gland or systemic treatment, metastases or prostate cancer-specific mortality. Adverse events were reported using Clavien-Dindo classification.
Results
Of all patients treated median (IQR) age was 66 years (60-71) and PSA 6.8ng/ml (4.0-9.5) with D'amico intermediate in 63.0% (1153/1829) and high-risk in 26.0% (475/1829). Median follow-up for all 1829 patients was 27.5 (13.5-55.3) months and 32.1 (17.0-58.1) for those with >/=6 months follow-up. 252/1379 (18.3%) had a repeat focal ablation due to residual or recurrent cancer; overall 39/1379 (2.8%) had salvage radiotherapy or brachytherapy and 53/1379 (3.8%) salvage radical prostatectomy. Kaplan-Meier 3, 5 and 7 year FFS was 93% (91-95%), 82% (79-86%), and 69% (64-74%), respectively (Figure 1). There was no statistically significant difference in 7 year FFS between intermediate and high-risk disease (68% [95% CI 62-75] and 65% [95% CI 56-74%], p=0.30). Adverse events with Clavien-Dindo score >2 occurred in 0.5% (9/1829).
Conclusions
Focal HIFU in treating eligible patients with clinically significant prostate cancer has good cancer control in the medium term.
Focal therapy aims to treat areas of cancer in order to confer oncological control whilst reducing treatment-related functional detriment. To report on oncological outcomes and adverse events following focal HIFU for treating non-metastatic prostate cancer.
Patients and Methods
An analysis of 1829 UK patients with non-metastatic prostate cancer prospectively recorded in the HEAT registry treated with Focal HIFU therapy (Sonablate500 and Sonablate 3G) at nine centres (17/11/2005-30/07/2020). Six months follow-up or greater was available in 1378 (75.3%). Failure-free survival (FFS) was primarily defined as avoidance of salvage whole-gland or systemic treatment, metastases or prostate cancer-specific mortality. Adverse events were reported using Clavien-Dindo classification.
Results
Of all patients treated median (IQR) age was 66 years (60-71) and PSA 6.8ng/ml (4.0-9.5) with D'amico intermediate in 63.0% (1153/1829) and high-risk in 26.0% (475/1829). Median follow-up for all 1829 patients was 27.5 (13.5-55.3) months and 32.1 (17.0-58.1) for those with >/=6 months follow-up. 252/1379 (18.3%) had a repeat focal ablation due to residual or recurrent cancer; overall 39/1379 (2.8%) had salvage radiotherapy or brachytherapy and 53/1379 (3.8%) salvage radical prostatectomy. Kaplan-Meier 3, 5 and 7 year FFS was 93% (91-95%), 82% (79-86%), and 69% (64-74%), respectively (Figure 1). There was no statistically significant difference in 7 year FFS between intermediate and high-risk disease (68% [95% CI 62-75] and 65% [95% CI 56-74%], p=0.30). Adverse events with Clavien-Dindo score >2 occurred in 0.5% (9/1829).
Conclusions
Focal HIFU in treating eligible patients with clinically significant prostate cancer has good cancer control in the medium term.
Introduction
Focal therapy aims to treat areas of cancer in order to confer oncological control whilst reducing treatment-related functional detriment. To report on oncological outcomes and adverse events following focal HIFU for treating non-metastatic prostate cancer.
Patients and Methods
An analysis of 1829 UK patients with non-metastatic prostate cancer prospectively recorded in the HEAT registry treated with Focal HIFU therapy (Sonablate500 and Sonablate 3G) at nine centres (17/11/2005-30/07/2020). Six months follow-up or greater was available in 1378 (75.3%). Failure-free survival (FFS) was primarily defined as avoidance of salvage whole-gland or systemic treatment, metastases or prostate cancer-specific mortality. Adverse events were reported using Clavien-Dindo classification.
Results
Of all patients treated median (IQR) age was 66 years (60-71) and PSA 6.8ng/ml (4.0-9.5) with D'amico intermediate in 63.0% (1153/1829) and high-risk in 26.0% (475/1829). Median follow-up for all 1829 patients was 27.5 (13.5-55.3) months and 32.1 (17.0-58.1) for those with >/=6 months follow-up. 252/1379 (18.3%) had a repeat focal ablation due to residual or recurrent cancer; overall 39/1379 (2.8%) had salvage radiotherapy or brachytherapy and 53/1379 (3.8%) salvage radical prostatectomy. Kaplan-Meier 3, 5 and 7 year FFS was 93% (91-95%), 82% (79-86%), and 69% (64-74%), respectively (Figure 1). There was no statistically significant difference in 7 year FFS between intermediate and high-risk disease (68% [95% CI 62-75] and 65% [95% CI 56-74%], p=0.30). Adverse events with Clavien-Dindo score >2 occurred in 0.5% (9/1829).
Conclusions
Focal HIFU in treating eligible patients with clinically significant prostate cancer has good cancer control in the medium term.
Focal therapy aims to treat areas of cancer in order to confer oncological control whilst reducing treatment-related functional detriment. To report on oncological outcomes and adverse events following focal HIFU for treating non-metastatic prostate cancer.
Patients and Methods
An analysis of 1829 UK patients with non-metastatic prostate cancer prospectively recorded in the HEAT registry treated with Focal HIFU therapy (Sonablate500 and Sonablate 3G) at nine centres (17/11/2005-30/07/2020). Six months follow-up or greater was available in 1378 (75.3%). Failure-free survival (FFS) was primarily defined as avoidance of salvage whole-gland or systemic treatment, metastases or prostate cancer-specific mortality. Adverse events were reported using Clavien-Dindo classification.
Results
Of all patients treated median (IQR) age was 66 years (60-71) and PSA 6.8ng/ml (4.0-9.5) with D'amico intermediate in 63.0% (1153/1829) and high-risk in 26.0% (475/1829). Median follow-up for all 1829 patients was 27.5 (13.5-55.3) months and 32.1 (17.0-58.1) for those with >/=6 months follow-up. 252/1379 (18.3%) had a repeat focal ablation due to residual or recurrent cancer; overall 39/1379 (2.8%) had salvage radiotherapy or brachytherapy and 53/1379 (3.8%) salvage radical prostatectomy. Kaplan-Meier 3, 5 and 7 year FFS was 93% (91-95%), 82% (79-86%), and 69% (64-74%), respectively (Figure 1). There was no statistically significant difference in 7 year FFS between intermediate and high-risk disease (68% [95% CI 62-75] and 65% [95% CI 56-74%], p=0.30). Adverse events with Clavien-Dindo score >2 occurred in 0.5% (9/1829).
Conclusions
Focal HIFU in treating eligible patients with clinically significant prostate cancer has good cancer control in the medium term.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}